A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity.
Cidara buys back rights to flu therapy from J&J for $85m
Share this article Cidara also closed a private placement of preferred stock worth $240m to buy back the rights for CD388 and advance its development.